Should I buy or sell AC Immune stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACIU shares. View ACIU analyst ratings or view top-rated stocks .

What is AC Immune's stock price target for 2024?

1 equities research analysts have issued 12-month target prices for AC Immune's stock. Their ACIU share price targets range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 572.3% from the stock's current price. View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts .

How have ACIU shares performed in 2024?

AC Immune's stock was trading at $5.00 at the beginning of the year. Since then, ACIU shares have decreased by 52.4% and is now trading at $2.38. View the best growth stocks for 2024 here .

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our ACIU earnings forecast .

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company earned $16.71 million during the quarter, compared to the consensus estimate of $16.36 million.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com . Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE) , Agenus (AGEN) , Aldeyra Therapeutics (ALDX) , Dynavax Technologies (DVAX) , Abeona Therapeutics (ABEO) , AVEO Pharmaceuticals (AVEO) , Catalyst Pharmaceuticals (CPRX) , Ocular Therapeutix (OCUL) , Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV) .

When did AC Immune IPO?

AC Immune (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACIU

AC Immune (ACIU) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free ACIU Stock Alerts

$2.38

-0.04 (-1.65%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.36
▼
$2.49
50-Day Range: $2.42
▼
$3.95
52-Week Range: $1.78
▼
$5.14

Volume: 369,337 shs
Average Volume: 165,898 shs
Market Capitalization: $235.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Get AC Immune alerts:

AC Immune MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 572.3% Upside
$16.00 Price Target
Short Interest: Healthy
0.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.78) to ($0.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

460th out of 918 stocks

Pharmaceutical Preparations Industry

201st out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
AC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
AC Immune has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.98% of the float of AC Immune has been sold short.
Short Interest Ratio / Days to Cover
AC Immune has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AC Immune has recently decreased by 3.84%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
AC Immune does not currently pay a dividend.
Dividend Growth
AC Immune does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACIU.

2.8

News and Social Media Coverage

News Sentiment
AC Immune has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for AC Immune this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
2 people have added AC Immune to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AC Immune insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of AC Immune is held by insiders.
Percentage Held by Institutions
51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AC Immune are expected to grow in the coming year, from ($0.78) to ($0.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AC Immune is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AC Immune is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AC Immune has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About AC Immune Stock (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ACIU Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACIU Stock News Headlines

April 18, 2024 | finance.yahoo.com

AC Immune SA (ACIU)

April 11, 2024 | finance.yahoo.com

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

April 18, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

March 20, 2024 | wsj.com

AC Immune S.A.

March 15, 2024 | markets.businessinsider.com

Buy Rating for AC Immune SA on Promising Alzheimer’s Vaccine Trial Design and Potential Accelerated Approval

March 15, 2024 | finance.yahoo.com

Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%

March 14, 2024 | finance.yahoo.com

ACIU Mar 2024 2.500 put

March 14, 2024 | globenewswire.com

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

April 18, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

February 22, 2024 | finanznachrichten.de

AC Immune SA: AC Immune Announces Upcoming Presentations at AD/PD 2024

February 22, 2024 | finance.yahoo.com

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

February 22, 2024 | globenewswire.com

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

February 21, 2024 | insidermonkey.com

5 Little-Known Penny Stocks With Massive Upside Potential

February 20, 2024 | finance.yahoo.com

ACIU May 2024 2.500 call

February 20, 2024 | finance.yahoo.com

ACIU Aug 2024 2.500 call

February 13, 2024 | investing.com

AC Immune Ltd (ACIU)

February 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for AC Immune SA Amid Promising Immunotherapy Program Developments

January 30, 2024 | finance.yahoo.com

Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround

January 22, 2024 | finanznachrichten.de

AC Immune SA: AC Immune to Regain Global Rights to Crenezumab and Semorinemab

January 22, 2024 | finance.yahoo.com

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

January 18, 2024 | finance.yahoo.com

AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?

January 8, 2024 | finance.yahoo.com

5 Small-Cap Stocks to Play the January Effect

January 3, 2024 | msn.com

AC Immune issues updates on Phase 2 studies, cash runway

January 3, 2024 | finance.yahoo.com

AC Immune (ACIU) Upgraded to Buy: Here's Why

January 3, 2024 | finance.yahoo.com

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

December 15, 2023 | msn.com

AC Immune Alzheimer's drug advanced into Phase 2b testing

December 15, 2023 | finance.yahoo.com

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial

See More Headlines

Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 4/26/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ACIU
CUSIP: N/A
CIK: 1651625
Web: www.acimmune.com
Phone: (121) 345-9121
Fax: 41-21-345-9120
Employees: 133
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.00
High Stock Price Target: $16.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +572.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-60,410,000.00
Net Margins: N/A
Pretax Margin: -366.34%
Return on Equity: -37.51%
Return on Assets: -33.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.22
Quick Ratio: 9.22

Sales & Book Value

Annual Sales: $16.48 million
Price / Sales: 14.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.12 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 98,900,000
Free Float: 94,350,000
Market Cap: $235.38 million
Optionable: Optionable
Beta: 1.00

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Andrea Pfeifer Ph.D. (Age 67)
Co-Founder, CEO & Director
Comp: $1.09M
Mr. Christopher Roberts (Age 34)
CFO & VP of Finance
Mr. Piergiorgio Donati (Age 53)
Chief Technical Operations Officer
Mr. Jean-Fabien Monin (Age 53)
Chief Administrative Officer
Mr. Howard Donovan (Age 48)
Chief HR Officer
Ms. Madiha Derouazi (Age 51)
Chief Scientific Officer
Dr. Gary Anthony Waanders Ph.D. (Age 60)
Senior VP of Investor Relations & Corporate Communications
Mr. Alexandre Caratsch (Age 58)
General Counsel
Mr. Julian Snow
VP of U.S. Finance & Corporate Development
Dr. David T. Hickman
Head of AD - SME

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ACIU Stock Analysis - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings or view top-rated stocks.
What is AC Immune's stock price target for 2024?: 1 equities research analysts have issued 12-month target prices for AC Immune's stock. Their ACIU share price targets range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 572.3% from the stock's current price.
View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts.
How have ACIU shares performed in 2024?: AC Immune's stock was trading at $5.00 at the beginning of the year. Since then, ACIU shares have decreased by 52.4% and is now trading at $2.38.
View the best growth stocks for 2024 here.
When is AC Immune's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our ACIU earnings forecast.
How were AC Immune's earnings last quarter?: AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company earned $16.71 million during the quarter, compared to the consensus estimate of $16.36 million.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?: 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of AC Immune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV).
When did AC Immune IPO?: AC Immune (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
How do I buy shares of AC Immune?: Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACIU) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AC Immune (ACIU) Stock Price, News & Analysis

AC Immune MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AC Immune Stock (NASDAQ:ACIU)

ACIU Stock Price History

ACIU Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ACIU Stock Analysis - Frequently Asked Questions

Overall MarketRank^™